Previous close | 2.6200 |
Open | 2.6300 |
Bid | 2.6600 x 200 |
Ask | 2.7100 x 200 |
Day's range | 2.5400 - 2.8000 |
52-week range | 0.7000 - 3.3400 |
Volume | |
Avg. volume | 6,377,234 |
Market cap | 495.942M |
Beta (5Y monthly) | 0.82 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.0300 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.41 |
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and CEO, will participate in a fireside chat on Tuesday, April 9, 2024, at 12:45 PM ET. The Esperion management team will also host investor meetings that same day. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and media section of the Esperion w
ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen) Outcomes subgroup analyses as poster presentations at the 2024 American College of Cardiology’s Annual Scientific Session (ACC.24) in Atlanta, Georgia. Additionally, the Company will participate in a moderated session in partnership with UT Southwestern Medical Center, host an industry expert theatre, and h